FGF21 is more accurate for predicting the onset of simple steatosis, while CK18 including M30 and M65ED are better non-invasive biomarkers for predicting the prognosis of NAFLD patients. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.